JPMorgan Chase & Co. upgraded UiPath's rating to "overweight" with a $28.00 price target, implying a 14.61% potential upside.
UiPath (NYSE:PATH) rating increased to "overweight" by research analysts at JPMorgan Chase & Co., from a previous "neutral" rating. The brokerage currently has a $28.00 price target on the healthcare company's stock, up from their previous price target of $22.00. This suggests a potential upside of 14.61% from UiPath's previous close.
March 13, 2024
16 Articles